Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Preferred Stock Liabilities (2016 - 2018)

Sutro Biopharma's Preferred Stock Liabilities history spans 3 years, with the latest figure at $187.2 million for Q3 2018.

  • For Q3 2018, Preferred Stock Liabilities changed N/A year-over-year to $187.2 million; the TTM value through Sep 2018 reached $187.2 million, changed N/A, while the annual FY2017 figure was $102.5 million, 0.0% changed from the prior year.
  • Preferred Stock Liabilities for Q3 2018 was $187.2 million at Sutro Biopharma, up from $102.5 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $187.2 million in Q3 2018 and bottomed at $102.5 million in Q4 2016.
  • The 3-year median for Preferred Stock Liabilities is $102.5 million (2016), against an average of $130.8 million.
  • The largest YoY upside for Preferred Stock Liabilities was 0.0% in 2017 against a maximum downside of 0.0% in 2017.
  • A 3-year view of Preferred Stock Liabilities shows it stood at $102.5 million in 2016, then changed by 0.0% to $102.5 million in 2017, then surged by 82.67% to $187.2 million in 2018.
  • Per Business Quant, the three most recent readings for STRO's Preferred Stock Liabilities are $187.2 million (Q3 2018), $102.5 million (Q4 2017), and $102.5 million (Q4 2016).